SHL is a fortress stock. Super hedged in terms of geography, lots of opportunity for growth (pathology sector, esp in the US, is very fragmented, and pathology needs scale).
SHL will survive any downturn. It’s not too expensive considering lower for longer interest rates.
Ann: CEO Presentation Half Year Results to 31 December 2019, page-8
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.87 |
Change
0.190(0.69%) |
Mkt cap ! $13.38B | |||
| Open | High | Low | Value | Volume |
| $27.68 | $27.96 | $27.53 | $16.17M | 582.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4547 | $27.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.95 | 2113 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| SHL (ASX) Chart |